20251215 171914 and 24 traded firm. Sagicor Select Funds was the volume leader with 40% of total volume. And the directors of Indus Pharma are reporting a decline in net profits to 174.6 million on revenues of 1.12 billion during the year ended October 31 this year. This compares with net profits of 221.2 million on revenues of $1.3 billion during the previous year. The company says the reduction in its revenues and profitability this year in comparison to last year was due to software challenges on the government's platform, which resulted in later rivals of out-of-stock items. This affected sales and revenue flows during the last two quarters of the year, as well as devastating impact of Hurricane Melissa. That is the end of the business roundup. To end this edition of Beyond the Headlines, a recap of our top stories. JPS announces 7% rate hike tied to November consumption. Slow but steady progress.
